Transdifferentiation

Across TCGA cell cohorts, RNA activity of the Transdifferentiation pathway is significantly associated with the drug response of multiple features, with the SKIN cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Veliparib, AZD3514, and AZD1480, each associated with the pathway in up to 1 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Veliparib grouped by Transdifferentiation-low versus -high activity in SKIN.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
SKIN	Veliparib →	-0.193	-0.154	.011	.012	3	1
SKIN	AZD3514 →	-0.560	-0.154	.049	.012	3	1
SKIN	AZD1480 →	-0.423	-0.154	.026	.012	3	1
SKIN	GW-2580 →	-0.195	-0.188	.037	.034	2	1
SKIN	LIMK1 inhibitor BMS4 →	+0.930	+0.167	.007	.021	2	1
SKIN	eEF2K Inhibitor →	-0.145	-0.167	.032	.021	2	1

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Veliparib by Transdifferentiation activity — SKIN

Explore this box plot interactively →